Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #25 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Piramal Pharma Limited (this stock) | 25,947 | 37.0 | -4.0% | -0.4% | — | 59 | 26 | 32 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 2,270 | -27 | -69 | ₹ |
| March 31, 2026 | 2,752 | 29 | -9 | ₹ |
| Dec. 31, 2025 | 2,140 | -104 | -136 | ₹ |
| Sept. 30, 2025 | 2,044 | -61 | -99 | ₹ |
| June 30, 2025 | 1,934 | -98 | -82 | ₹ |
| March 31, 2025 | 2,754 | 257 | 154 | ₹ |
| Dec. 31, 2024 | 2,204 | 50 | 4 | ₹ |
| Sept. 30, 2024 | 2,242 | 103 | 23 | ₹ |
| June 30, 2024 | 1,951 | -67 | -89 | ₹ |
| March 31, 2024 | 2,552 | 215 | 101 | ₹ |
| Dec. 31, 2023 | 1,959 | 5 | 10 | ₹ |
| Sept. 30, 2023 | 1,911 | 20 | 5 | ₹ |
| June 30, 2023 | 1,749 | -121 | -99 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 8,869 | -233 | -326 |
| March 31, 2025 | 9,151 | 342 | 91 |
| March 31, 2024 | 8,171 | 120 | 18 |
| March 31, 2023 | 7,082 | -174 | -186 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 1,653 | -826 | -39 | 890 | 763 |
| March 31, 2025 | 892 | -477 | -441 | 664 | 228 |
| March 31, 2024 | 1,005 | -434 | -422 | 712 | 292 |
| March 31, 2023 | 484 | -1,339 | 818 | 965 | -481 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 17,965 | 8,163 | 6,835 | 1,196 | 4,300 | 7,192 | 4,758 | 1,200 | 4,451 | 3,064 |
| March 31, 2025 | 15,678 | 8,125 | 6,801 | 1,506 | 3,214 | 5,797 | 3,766 | 369 | 4,176 | 2,313 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
